5-fluoruracil, doxorubicin and ciclophosphamyde (FAC) followed by docetaxel (TXT) as adjuvant chemotherapy in node positive early breast cancer: Toxicity and safety

被引：0
|
作者：
Ratti, R. [1 ]
Coccorullo, Z. [1 ]
Guarneri, D. [1 ]
Addamo, G. [1 ]
Colloca, G. [1 ]
Venturino, A. [1 ]
Campora, E. [1 ]
机构：
[1] Stabilimento Osped Sanremo, San Remo, Italy
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：138 / 138
页数：1
相关论文
共 50 条
  • [41] P53 EXPRESSION IN NODE-POSITIVE BREAST CANCER PATIENTS RECEIVING DOCETAXEL-BASED ADJUVANT CHEMOTHERAPY
    An, H. J.
    Lee, H. -J.
    Gong, G.
    Kim, K. -P.
    Ahn, J. -H.
    Jung, K. H.
    Kim, J. E.
    Son, B. H.
    Ahn, S. -H.
    Kim, S. -B.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 17 - 17
  • [42] Comparison of Docetaxel, Doxorubicin and Cyclophosphamide (TAC) with 5-Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer: A Phase III Clinical Trial
    Omidvari, Shapour
    Hosseini, Sare
    Ashouri, Yaghoub
    Tahmasebi, Sedigheh
    Talei, Abdolrasoul
    Nasrolahi, Hamid
    Ahmadloo, Niloofar
    Ansari, Mansour
    Mosalaei, Ahmad
    Mohammadianpanah, Mohammad
    [J]. MIDDLE EAST JOURNAL OF CANCER, 2011, 2 (02) : 51 - 58
  • [43] Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin, and cyclophosphamide as adjuvant chemotherapy for early-stage breast cancer
    Abe, H.
    Umeda, T.
    Kawai, Y.
    Tanaka, M.
    Shimizu, T.
    Chou, H.
    Kubota, Y.
    Mekata, E.
    Kurumi, Y.
    Tani, T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer.
    Goldstein, LJ
    O'Neill, A
    Sparano, J
    Perez, E
    Shulman, L
    Martino, S
    Davidson, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 7S - 7S
  • [45] Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin and cyclophosphamide regimen (TAC) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) in early breast cancer at the Mexican Social Security Institute (IMSS) Mexico
    Valle-Solis, Aura A. Erazo
    Olivares, Guillermo
    Lazaro, Miguel
    Maurel, Frederique
    Robles, Jesus
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 107 - 107
  • [46] A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer
    Yardley, Denise A.
    Burris, Howard A., III
    Farley, Cindy P.
    Barton, John H.
    Peacock, Nancy W.
    Spigel, David R.
    Greco, F. Anthony
    Hainsworth, John D.
    [J]. CLINICAL BREAST CANCER, 2008, 8 (03) : 242 - 248
  • [47] Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients:: The FNCLCC PACS 01 trial
    Roche, Henri
    Fumoleau, Pierre
    Spielmann, Marc
    Canon, Jean-Luc
    Delozier, Thierry
    Serin, Daniel
    Symann, Michel
    Kerbrat, Pierre
    Soulie, Patrick
    Eichler, Francoise
    Viens, Patrice
    Monnier, Alain
    Vindevoghel, Anita
    Campone, Mario
    Goudier, Marie-Josephe
    Bonneterre, Jacques
    Ferrero, Jean-Marc
    Martin, Anne-Laure
    Geneve, Jean
    Asselain, Bernard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (36) : 5664 - 5671
  • [48] Randomised trial:: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer
    Kümmel, S
    Krocker, J
    Kohls, A
    Breitbach, GP
    Morack, G
    Budner, M
    Blohmer, JU
    Elling, D
    [J]. BRITISH JOURNAL OF CANCER, 2006, 94 (09) : 1237 - 1244
  • [49] Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer
    S Kümmel
    J Krocker
    A Kohls
    G-P Breitbach
    G Morack
    M Budner
    J-U Blohmer
    D Elling
    [J]. British Journal of Cancer, 2006, 94 : 1237 - 1244
  • [50] Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: The Cancer and Leukemia Group B experience
    Muss, Hyman B.
    Berry, Donald A.
    Cirrincione, Constance
    Budman, Daniel R.
    Henderson, I. Craig
    Citron, Marc L.
    Norton, Larry
    Winer, Eric P.
    Hudis, Clifford A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (24) : 3699 - 3704
12345